AAA
JAZZ icon

Affinity Asset Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Affinity Asset Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,000
Closed -$3.29M – 106
2025
Q3 		$3.29M Hold
25,000
– – 0.29% 63
2025
Q2 		$2.65M Buy
+25,000
New +$2.72M 0.36% 51

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Affinity Asset Advisors's JAZZ Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 25,000 shares — an estimated $3.29M sold.

Affinity Asset Advisors first reported a position in JAZZ in Q2 2025 and held it in 2 quarters. The position peaked at $3.29M in Q3 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 25,000 Jazz Pharmaceuticals shares in Q4 2025, an estimated $3.29M.
  • Affinity Asset Advisors first reported a position in Jazz Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Affinity Asset Advisors's Jazz Pharmaceuticals position peaked at $3.29M in Q3 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.